Status:
COMPLETED
Oxcarbazepine Versus Placebo in Childhood Autism
Lead Sponsor:
University of Medicine and Dentistry of New Jersey
Collaborating Sponsors:
National Alliance for Research on Schizophrenia and Depression
Conditions:
Autism
Eligibility:
All Genders
5-17 years
Phase:
NA
Brief Summary
The proposed study is designed to assess the effectiveness of treatment with Oxcarbazepine vs. placebo in childhood/adolescent autism. This is a twelve-week study involving twenty subjects between the...
Detailed Description
The proposed study is designed to assess the effectiveness of treatment with Oxcarbazepine vs. placebo in childhood/adolescent autism. This is a twelve-week study involving twenty subjects between the...
Eligibility Criteria
Inclusion
- Subject has autism.
- Subject is between five and seventeen years of age
- Subject is not hospitalized.
Exclusion
- Subject has been diagnosed with a psychopathic disorder or a mood disorder, including depression or bipolar disorder.
- Subject has displayed self-injurious behavior.
- Subject has an active seizure disorder or epilepsy.
- Subject has an unstable medical illness.
- Subject has undergone brain injury.
- Subject has a history of diabetes.
- Subject has a history of prior treatment with oxcarbazepine of 600 mg/day for 6 weeks.
- Subject has used other study drugs within the previous 30 days.
- Subject is a pregnant female or unwilling to use acceptable contraception if sexually active.
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00467753
Start Date
April 1 2006
End Date
December 1 2011
Last Update
January 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Child and Adolescent Psychiatry at the University Behavioral Healthcare Building, UMDNJ-RWJMS
Piscataway, New Jersey, United States, 08854